Abstracts tagged "aspirin"

Abstract Number: 1856 • 2018 ACR/ARHP Annual Meeting
Low Aspirin Use and High Prevalence of Preeclampsia Risk Factors Among Pregnant Women in a Multi-National SLE Inception Cohort
Arielle Mendel, Sasha Bernatsky and Evelyne Vinet, Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Because aspirin reduces the risk of preeclampsia in high-risk pregnancies by more than half, best practice guidelines recommend that aspirin be initiated in pregnant…
Abstract Number: 2045 • 2017 ACR/ARHP Annual Meeting
Prophylaxis of Ischemic Disease in Giant Cell Arteritis Patients: An Application of a “Big Data” Tracking Tool in the Electronic Health Record in an University-Based Medical Center
Meera Subash¹, Zunera Tahir² and Arthur Kavanaugh³, ¹Internal Medicine, University of California, San Diego, San Diego, CA, ²Internal Medicine, Div of Rheumatology, Allergy, and Immunology, University of California, San Diego, San Diego, CA, ³Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: The primary objective of this study was to better characterize the prescribed rates of aspirin prophylaxis for ischemic considerations in patients diagnosed with Giant…
Abstract Number: 2788 • 2017 ACR/ARHP Annual Meeting
The Risk of Major Toxicity with Aspirin for Primary Cardiovascular Prevention in Rheumatoid Arthritis Patients Using Nsaids: A Secondary Cohort Analysis of a Randomized Controlled Clinical Trial
Daniel H. Solomon¹, Peter Libby², Qiuquing Wang³, Katherine E Wolski⁴, Lisa M Wisniewski⁴, Neville Yeomans⁵, Michael Lincoff⁶, Steven E Nissen⁷ and M. Elaine Husni⁸, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Cardiology, Brigham and Women's Hospital, Boston, MA, ³Cleveland Clinic, Cleveland, OH, ⁴Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ⁵Western Sydney Medical School, Sydney, Australia, ⁶Cardiology, Cleveland Clinic Foundation, Cleveland, OH, ⁷Cardiovascular Medicine, Chair, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: There are relatively clear guidelines for the use of low dose aspirin in the general population for primary cardiovascular (CV) prevention, but the risk-benefit…
Abstract Number: 1066 • 2016 ACR/ARHP Annual Meeting
History of Lupus Nephritis Is an Independent Risk Factor for Thrombosis in Systemic Lupus Erythematosus Patients with Antiphospholipid Antibodies
Vinicius Domingues¹, Janet Nwaukoni², Jill P. Buyon³ and H. Michael Belmont⁴, ¹Rheumatology, NYU Langone Medical Center, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Few studies have analyzed the risk factors for thrombosis in Systemic Lupus Erythematosus (SLE) patients with antiphospholipid antibodies (aPL) and most had small sample…
Abstract Number: 743 • 2016 ACR/ARHP Annual Meeting
Long-Term Hydroxychloroquine Therapy and Low-Dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Serena Fasano¹, Michele Iudici², Ilenia Pantano³, Luciana Pierro³ and Gabriele Valentini⁴, ¹Internal and Experimental Medicine Naples, Italy, Rheumatology Unit, Second University of Naples, Naples, Italy, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Rheumatology Unit, Second University of Naples, Naples, Italy, ⁴Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy
Background/Purpose: Hydroxychloroquine (HCQ) is a mainstay of treatment in patients with SLE. It has been demonstrated to reduce disease activity and prevent damage accrual and…
Abstract Number: 905 • 2016 ACR/ARHP Annual Meeting
Platelet Activation, As Measured By Plasma Soluble Glycoprotein VI, Is Not Associated with Disease Activity or Ischaemic Events in Giant Cell Arteritis
Richard Conway¹, Anne Madigan², Laura Helbert³, Niamh Redmond⁴, Eimear Dunne⁵, Eamonn S. Molloy⁶, Dermot Kenny⁵ and Geraldine M. McCarthy⁷, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ³Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ⁴UCD Clinical Research Centre, Dublin, Ireland, ⁵Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ⁶Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin, Ireland, ⁷Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland
Background/Purpose: Patients with Giant Cell Arteritis (GCA) have an increased risk of devastating cranial ischaemic complications including vision loss and stroke. The BSR guidelines recommend…
Abstract Number: 2130 • 2015 ACR/ARHP Annual Meeting
Primary Prevention of Myocardial Infarction in Rheumatoid Arthritis Using Low-Dose Aspirin: A Case-Crossover Study
Josefina Durán Santa Cruz¹, Yuqing Zhang² and David T. Felson³, ¹Department of Rheumatology, Pontificia Universidad Católica de Chile School of Medicine, Santiago, Chile, ²Clinical Epidemilogy and Training Unit, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Subjects with rheumatoid arthritis (RA) are at a higher risk of developing cardiovascular (CV) disease which is the leading cause of death in subjects…
Abstract Number: 2148 • 2013 ACR/ARHP Annual Meeting
Use Of Low Dose Aspirin Is Associated With Reduced Medial Tibial Cartilage Loss In Symptomatic Osteoarthritis: DATA From A Cohort Study
Anita Wluka¹, Changhai Ding², Yuanyuan Wang³, Graeme Jones⁴, Andrew Teichtahl⁵ and Flavia Cicuttini¹, ¹Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, ²Musculoskeletal Unit, Menzies Research Institute Tasmania, University of Tasmania, Hobart,7000, Australia, ³Monash University, Melbourne, Australia, ⁴Menzies Research Institute Tasmania, University of Tasmania, HOBART, Australia, ⁵Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
Background/Purpose: Inflammation and vascular disease have recently been shown to play a role in the pathogenesis of osteoarthritis (OA). Low dose aspirin is commonly used…
Abstract Number: 1992 • 2013 ACR/ARHP Annual Meeting
Trends In Outpatient Treatment Of Gout In The US: From 1993 To 2009
Eswar Krishnan and Linjun Chen, Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Gouty arthritis (gout) is primarily managed in the community by primary care providers. Relatively little is known about the treatment patterns as well as…
Abstract Number: 704 • 2013 ACR/ARHP Annual Meeting
Evaluating The Effects Of Combination Aspirin and Dipyridamole (asasantin retard) On Platelet Function, Oxidative Stress and Peripheral Vascular Function In Primary Raynaud’s Phenomenon and Systemic Sclerosis
John D. Pauling¹, Jacqueline A. Shipley¹, Darren Hart¹, Ginger L. Milne² and Neil J McHugh^1,3, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, ³Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: There is evidence of enhanced platelet activation in Raynaud’s phenomenon (RP), particularly in systemic sclerosis (SSc). Upon activation, platelets release vasoconstrictive mediators (e.g. thromboxane…
Abstract Number: 587 • 2013 ACR/ARHP Annual Meeting
Low-Dose Aspirin Has An Anti-Platelet Effect In Systemic Lupus Erythematosus
Michelle Petri¹, Laurence S. Magder² and Thomas Kickler¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Thrombosis is increased in SLE patients, with and without antiphospholipid antibodies. Aspirin and hydroxychloroquine are thought to have anti-platelet effects. We determined whether these…
Abstract Number: 2459 • 2012 ACR/ARHP Annual Meeting
Efficacy of Aspirin for the Prevention of the First Thrombo-Embolic Events in Patients with Antiphospholipid Antibodies: A Metanalysis of Literature Data
Laurent Arnaud¹, Alexis Mathian², Amelia Ruffatti³, Maria Tecktonidou⁴, Ricard Cervera⁵, Ricardo Forastiero⁶, Vittorio Pengo⁷, Marc Lambert⁸, Stephane Zuily⁹, Denis Wahl⁹ and Zahir Amoura¹, ¹Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ³Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy, ⁴First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ⁵Autoimmune Diseases, Hospital Clínic of Barcelona, Barcelona, Spain, ⁶Favaloro University, Argentina, ⁷Clinical Cardiology, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy, ⁸Medecine Interne Lilloise, Internal Medicine University Lille Hospital, Lille, Lille, France, ⁹Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy University Hospital, Université de Lorraine & INSERM U961, Vandoeuvre-Les-Nancy, France
Background/Purpose: Whether aspirin is needed in patients with antiphospholipid antibodies (aPL+) for prevention of a first thrombotic event is controversial. The aim of this metaanalysis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].